, maximum inactivation rate constant; K I , inhibitor concentration when the rate constant of inactivation reaches half of k inact ; IC 50 , concentration of the inhibitor producing 50% decrease in enzyme activity. Summary: Mechanism-based inactivation (MBI) of cytochrome P450 3A (CYP3A) often causes serious drug-drug interactions. To examine species differences in MBI of CYP3A between humans and rodents, we compared MBI potencies of five representative CYP3A inhibitors in human, rat and mouse liver microsomes. Among the inhibitors studied, erythromycin and clarithromycin exhibited markedly weaker MBI effects on CYP3A activity in rat and mouse liver microsomes compared to human liver microsomes. Results of spectroscopic experiments showed that erythromycin and clarithromycin form a metabolic intermediate complex with human liver microsomes but not with rat or mouse liver microsomes. In contrast, troleandomycin, diltiazem and nicardipine form a metabolic intermediate complex with rat and mouse liver microsomes, although some differences in MBI potency among species were observed. Parameters for MBI potency (kinact/KI ratio) and reversible inhibition (IC50) were negatively correlated (r＝-0.820, p＝0.0003), suggesting that the different affinities of CYP3A inhibitor for CYP3A may partly contribute to the different MBI potencies of inhibitor among species. Taken together, the results suggest that there are species differences in MBI of CYP3A in humans, rats and mice, which should be considered when rodents are used as in vivo models for MBI-mediated drug-drug interaction study.
Introduction
Drug-drug interactions (DDI) arising from inhibition of cytochrome P450 (CYP) may lead to serious adverse drug reactions. 1) In the inhibition of CYP, mechanismbased inactivation (MBI) has long-term effect on pharmacokinetic DDI since inactivation of CYP by formation of a stable complex with a metabolite is irreversible and synthesis of a new enzyme is required to restore the functional deficit. 2, 3) The CYP3A subfamily, participating in the metabolism of more than half of currently available therapeutic drugs, is subjected to MBI by a number of drugs because of its broad substrate specificity. 4, 5) Some drugs (e.g., mibefradil) have been withdrawn from the market due to unacceptable risk of potentially dangerous DDI resulting from inactivation of CYP3A. 3, 4) Consequently, attention has been paid to the prediction of MBI arising from CYP3A in the development of new drug entities to avoid unanticipated DDI.
To assess the potential of drug candidates to cause MBI of CYP3A, in vitro experiments have been performed to evaluate the degree of time-and concentration-dependent inactivation using human liver microsomes (HLM), cDNA-expressed enzymes and human hepatocytes. 4, 6, 7) In addition, models for predicting the degree of clinical in vivo DDI based on inactivation parameters have been developed, but accuracy of prediction is uncertain. [7] [8] [9] [10] [11] Experimental animals, especially rodents, are generally used for in vivo pharmacokinetic studies from early-to late-stage development of new drugs. However, there have been only a few attempts to predict clinical MBI-mediated DDI in animals, because of species differences in substrate specificities and inhibitor sensitivities. [12] [13] [14] In fact, species differences in CYP3A inactivation via MBI have been less studied. Little is known about the accuracy of prediction of the potential of MBImediated DDI using animals. Recently, some researchers have attempted to construct CYP3A humanized mice to solve problems of species differences in CYP3A for humans and animals, 15, 16) although the usefulness of these CYP3A humanized mice in DDI study has not been clarified.
Mechanism-based inactivation is common for CYP3A substrates that contain an amine functional group and undergo N-dealkylation.
17)
Macrolide antibiotics, such as erythromycin (ERM), clarithromycin (CAM) and troleandomycin (TAO), and calcium channel blockers, such as diltiazem (DTZ) and nicardipine (NCD), are well known CYP3A inhibitors via MBI in humans. [17] [18] [19] [20] [21] [22] Each of them possesses a tertiary amine that can be metabolized to a nitroso group and forms a stable metabolic intermediate complex with the heme of human CYP3A. 9, 22) However, it is unclear whether MBI potencies of CYP3A inhibitors in humans are comparable to those in experimental animals.
The present study examines species differences in MBI of CYP3A between humans and rodents. We compared MBI potencies of representative CYP3A inhibitors (ERM, CAM, TAO, DTZ and NCD) in HLM, rat liver microsomes (RLM) and mouse liver microsomes (MLM). In addition, we monitored the formation of a metabolic intermediate complex and examined possible factors explaining species differences in MBI potencies of CYP3A inhibitors. Direct comparison of MBI potencies of CYP3A inhibitors between humans and rodents should provide useful information for MBI-mediated DDI study using experimental animals including CYP3A humanized animals.
Materials and Methods
Chemicals: Triazolam (TRZ), ERM, CAM and TAO were purchased from Wako Pure Chemicals (Osaka, Japan). DTZ and NCD were purchased from Sigma-Aldrich (St. Louis, MO). 1?-Hydroxy TRZ (1?-OH TRZ) and 4-hydroxy TRZ (4-OH TRZ) were supplied by Nihon Upjohn Co. (Tokyo, Japan). Other reagents were of analytical or HPLC grade and obtained commercially.
Liver microsomes: Pooled HLM prepared from 25-30 donors were purchased from BD Gentest (Woburn, MA). Pooled RLM were prepared from 6-weekold male Sprague-Dawley rats purchased from SLC (Shizuoka, Japan). Pooled MLM were prepared from 9-week-old male C57BL/6Cr mice purchased from SLC.
Liver tissues from untreated rats (pooled from 3 animals) and mice (pooled from 8 animals) were homogenized in ice-cold 1.15% potassium chloride and microsomes were isolated by differential centrifugation as described previously. 23) The microsomal pellet was resuspended in 100 mM sodium phosphate buffer (pH 7.4) and stored at -809 C until use. Protein concentrations were determined using a DC protein assay (Bio-Rad, Hercules, CA) according to the manufacturer's instructions.
Microsomal incubations: Basically, microsomes were preincubated in a reaction mixture containing 100 mM potassium phosphate buffer (pH 7.4), 0.1 mM EDTA and TRZ for 1 min at 379 C. The reaction was started by adding an NADPH-generating system (0.5 mM NADP ＋ , 2 mM glucose-6-phosphate, 1 IU/mL glucose-6-phosphate dehydrogenase and 4 mM MgCl2) in a final volume of 250 mL. After incubation, the reaction was stopped by the addition of 100 mL acetonitrile followed by 50 mL internal control (1 mg/mL oxazepam in methanol). The mixtures were centrifuged at 15,000 rpm for 5 min to remove protein and the supernatants were subjected to high-performance liquid chromatography (HPLC) for determination of respective metabolites as described below.
HPLC analysis for 1?-OH TRZ and 4-OH TRZ: Determination of 1?-OH TRZ and 4-OH TRZ was carried out using a Hitachi L-7000 model of HPLC system (Tokyo, Japan) and CAPCELL PAK C18 UG120 column (4.6 mm×250 mm, 5 mm; Shiseido, Tokyo, Japan). The mobile phase contained 10 mM potassium phosphate buffer (pH 7.4), acetonitrile and methanol (60/30/10, v/v/v), at a flow rate of 1 mL/min. The eluent was monitored at a wavelength of 220 nm.
Immunoinhibition assay: Immunoinhibition assay of TRZ metabolism was performed by preincubation of HLM, RLM or MLM (25 mg) with rabbit polyclonal antiserum for CYP3A2 (Xenotech, Tokyo, Japan) or pre-immune rabbit serum for 10 min at room temperature in a final volume of 25 mL. The mixtures were diluted with a reaction mixture containing 200 mM TRZ, and the reactions were started by the addition of the NADPH-generating system in a final volume of 250 mL. The samples were incubated for an additional 20 min at 379 C. All incubations were performed in two independent determinations. Data are expressed as % remaining activity relative to the activity in the absence of serum.
Mechanism-based inactivation (MBI) by CYP3A inhibitors: MBI assays were performed as recommended previously. 2) HLM, RLM or MLM (1 mg/mL) was preincubated at 379 C with various concentrations of inhibitors in reaction mixtures each containing 1 mM NADPH instead of the NADPH-generating system. At various times, aliquots of the preincubation mixtures (25 mL) were diluted 10-fold with fresh reaction mixture containing 1 mM NADPH and 400 mM TRZ to a final volume of 250 mL. A saturating concentration of TRZ was used to measure the remaining catalytically active CYP3A. The reactions were continued for 5 min and terminated by acetonitrile as described above. Data were corrected for loss of activity in control incubation (no inhibitor) at each time. All incubations were performed in two independent determinations.
To estimate inactivation parameters, the natural logarithm of the percentage of remaining activity was plotted against preincubation time. The observed inactivation rate constants (kobs) were determined from the slopes of the initial linear decline in activity at each inhibitor concentration. The parameters kinact and KI were obtained from a direct plot of inhibitor concentration (I) versus kobs according to the nonlinear least-squares method using DeltaGraph 5 (Red Rock Software, Salt Lake, UT) according to the following equation:
where kobs is the pseudo first-order rate constant of inactivation at the inhibitor concentration (I), kinact is the maximum inactivation rate constant, and KI is the inhibitor concentration when the rate constant of inactivation reaches half of kinact.
Formation of P450-Iron(II)-metabolic intermediate complex: The incubation mixture contained HLM (2 mg/mL), RLM (3 mg/mL) or MLM (3 mg/mL) in 100 mM phosphate buffer (pH 7.4), 10 mM MgCl2 and 1 mM NADPH in a final volume of 2 mL. Equal volumes were allotted to sample and reference cuvettes and a baseline was recorded. ERM (100 mM), CAM (100 mM), TAO (20 mM), DTZ (10 mM) or NCD (10 mM) was added to the sample cuvette, whereas the reference cuvette received an equal volume of a vehicle (methanol, final concentration of less than 1%). Difference spectra for the reference and sample cuvettes were recorded using a dual-beam spectrophotometer (Hitachi U-3300) by scanning from 400 to 500 nm. The difference spectra were recorded immediately (0 min) after addition of the inhibitor and at 20-min incubation at 379 C.
Reversible inhibition by CYP3A inhibitors: HLM, RLM or MLM (0.1 mg/mL) was simultaneously incubated with 100 mM TRZ and several concentrations of inhibitors in the presence of the NADPH-generating system for 5 min at 379 C in a final volume of 250 mL. Since the period of product formation was kept brief and inhibitors were coincubated with a substrate as reported previously, inhibition parameters were considered to reflect primarily the affinity of the inhibitor to CYP3A enzymes. 22, 24) The activity of 4-OH TRZ formation was then determined by HPLC as described above and expressed as a percentage relative to the activity in the absence of inhibitors. All incubations were performed in two independent determinations. The concentration of the inhibitor producing 50% decrease in the activity of CYP3A (IC50 value) was estimated using DeltaGraph5 nonlinear regression analysis as described previously. 19) Results CYP3A specificity of 1?-and 4-hydroxylation of TRZ in HLM, RLM and MLM: Figure 1 shows the remaining activity of TRZ hydroxylation in the presence of anti-CYP3A2 serum or pre-immune serum. In HLM and MLM, the formation of 1?-OH TRZ and 4-OH TRZ was almost completely inhibited by anti-CYP3A2 serum. The formation of 4-OH TRZ in RLM was also almost completely inhibited by anti-CYP3A2 serum, but 11% of 1?-OH TRZ formation was not inhibited. These results suggest that TRZ metabolism is highly specific to CYP3A in HLM, RLM and MLM; however, 4-OH TRZ formation appears to be a more suitable marker for CYP3A activity. Therefore, we monitored the formation of 4-OH TRZ as a marker of CYP3A activity in the following experiments.
MBI effects of CYP3A inhibitors: To examine species differences in MBI of CYP3A for humans and ro- dents, we compared MBI potencies of representative CYP3A inhibitors (ERM, CAM, TAO, DTZ and NCD) in HLM, RLM and MLM. The effects of time-and concentration-dependent inactivation on the formation of 4-OH TRZ by CYP3A inhibitors are shown in Figure 2 , and estimated parameters for inactivation (KI, kinact and kinact/KI ratio) are listed in Table 1 . In HLM, all CYP3A inhibitors studied inhibited the formation of 4-OH TRZ in a time-and concentration-dependent manner, showing a representative pattern of MBI. In contrast, the inactivation effects of CYP3A inhibitors on the formation of 4-OH TRZ in RLM and MLM were different from those in HLM. Notably, the inactivation effects of ERM and CAM in RLM and MLM were remarkably weaker than The K I and k inact values were calculated as described in Material and Methods using the data shown in Figure 2 . The units of K I , k inact and k inact /K I ratio are mM, min -1 and 10 -3 ･min -1 ･mM -1 , respectively. n.c., not calculable because of weak inactivation effect.
Fig. 3. Formation of metabolic intermediate complex by CYP3A inhibitors in HLM (A), RLM (B) and MLM (C)
The incubation mixture contained HLM (2 mg/mL), RLM (3 mg/mL) or MLM (3 mg/mL) with 1 mM NADPH. After running baseline, ERM (100 mM), CAM (100 mM), TAO (20 mM), DTZ (10 mM) or NCD (10 mM) was added to the sample cuvette, whereas the reference cuvette received an equal volume of a vehicle. Difference spectra between reference and sample cuvettes were recorded using a dual-beam spectrophotometer. Representative 20-min difference spectra for incubation of inhibitors with HLM, RLM and MLM are shown. those in HLM. In RLM, ERM caused no significant timedependent inactivation so that parameters for the inactivation of enzymes could not be estimated. The kinact and the kinact/KI ratio in MLM for ERM were approximately 4-fold lower than those in HLM. Similarly, kinact and kinact/KI ratios for CAM in RLM and MLM were much lower than those in HLM. On the other hand, kinact/KI ratios for TAO and DTZ were comparable between HLM and MLM, whereas the kinact/KI ratio in RLM was lower than in HLM or MLM. In all species, NCD showed a high kinact/KI ratio and nearly the same kinact.
Formation of P450-Iron(II)-metabolic intermediate complex: The formation of a metabolic intermediate complex with CYP3A can be detected by display of a spectrum with absorbance maximum around 455 nm, a characteristic Soret peak. 17) To investigate possible mechanistic differences in the inactivation of CYP3A for HLM, RLM and MLM, we monitored the formation of a metabolic intermediate complex by scanning spectral changes between 400-500 nm. As shown in Figure 3A , representative spectral changes with a Soret peak were observed when ERM or CAM was incubated with HLM. Similarly, incubation of TAO, DTZ and NCD with RLM or MLM resulted in spectral change (Figs. 3B and 3C) . In contrast, incubation of ERM and CAM with RLM or MLM showed no spectral change.
Reversible inhibition effects of CYP3A inhibitors: Since differences in potencies of MBI by CYP3A inhibitors for HLM, RLM and MLM may be partly dependent on differences in affinities of inhibitors for CYP3A, we determined reversible inhibition parameter (IC50) for each inhibitor as a marker reflecting binding affinity for CYP3A. The relationship between inhibitor concentration and uninhibited percentage of the formation of 4-OH TRZ in HLM, RLM and MLM is shown in Figure  4 , and IC50 are listed in Table 2 . All CYP3A inhibitors studied inhibited the formation of 4-OH TRZ in a concentration-dependent manner, but some species differences in IC50 were observed. IC50 of ERM and CAM observed in RLM and MLM were much higher than in The IC 50 values were calculated by nonlinear regression analysis using the data shown in Figure 4 . Fig. 5 . Relationship between k inact /K I ratios (MBI potency) and IC 50 (reversible inhibition) for CYP3A inhibitors The k inact /K I ratio derived from MBI experiment was plotted against IC 50 derived from reversible inhibition experiment. The relationship between k inact /K I ratio and IC 50 was determined by linear regression analysis. Data of inhibition by ERM in RLM were excluded from this plot, since the inactivation parameter for MBI could not be calculated because of weak inactivation effect. H, R and M represent data from humans, rats and mice, respectively. The correlation coefficient (r) and significant (p) are also shown.
HLM, whereas IC50 of DTZ observed in RLM and MLM were approximately 3-fold lower than in HLM. IC50 of TAO observed in RLM was approximately 3-fold higher than in HLM and MLM. Among the CYP3A inhibitors studied, IC50 of NCD was lowest for any species (º2 mM).
Relationship between kinact/KI ratios (MBI potency) and IC50 (reversible inhibition effect): To examine the relationship between MBI potency and affinity for CYP3A of the five CYP3A inhibitors, the kinact/KI ratio was plotted against IC50. As shown in Figure 5 , kinact/KI ratios were negatively correlated with IC50 (r＝-0.820, p＝0.0003).
Discussion
In this study, we compared MBI potencies of CYP3A inhibitors for HLM, RLM and MLM using 4-OH TRZ formation as a marker of CYP3A activity. MBI potencies of CYP3A inhibitors exhibited species differences in humans, rats and mice that could be partly explained by different affinities of inhibitor for CYP3A.
Among the CYP3A inhibitors studied, ERM and CAM showed marked differences in CYP3A inactivation according to species. Although ERM and CAM remarkably produced time-and concentration-dependent inactivation of CYP3A in HLM, these inactivation effects including MBI potencies in terms of kinact/KI ratios were much weaker in RLM and MLM (Figs. 2A, 2B and Table 1 ). In addition, the results of spectroscopic experiments showed that ERM and CAM cause spectral change characterized by a Soret peak with HLM but neither with RLM nor MLM (Fig. 3) . Taken together, the results suggest that ERM and CAM may cause significant MBI in human CYP3A but cause no or much weaker MBI in rat and mouse CYP3A. These species differences in CYP3A inac-tivation by ERM and CAM in humans, rats and mice display species differences in CYP3A inactivation that might limit the use of rodents as in vivo models for prediction of MBI-mediated DDI.
In contrast to ERM and CAM, time-and concentration-dependent inactivation effects on CYP3A activity of NCD in HLM were comparable to those in RLM and MLM (Fig. 2E) . NCD showed a high kinact/KI ratio and almost the same kinact in all species ( Table 1) . In addition, the results of spectroscopic experiments showed that NCD formed a metabolic intermediate complex with RLM and MLM (Figs. 3B and 3C) . These results suggest that there is negligible species differences in CYP3A inactivation by NCD. Although there has been no report on CYP3A inactivation by NCD in animals, NCD may be a common potent inactivator of CYP3A in humans, rats and mice. In the case of CYP3A inhibitors (e.g., NCD) for which MBI effects in humans are reproducible in animals in vitro, it may be possible to use animals as in vivo models for study of MBI-mediated DDI.
The time-dependent inactivation of CYP3A and formation of a metabolic intermediate complex by TAO and DTZ were also observed in RLM and MLM (Figs. 2C, 2D, 3B and 3C), but some differences in the degree of inactivation among species were found ( Table 1) . TAO exhibited lower kinact and kinact/KI ratio in RLM than in HLM and MLM, suggesting that the potency of MBI by TAO was smaller in rats than in humans and mice. DTZ showed lower kinact/KI ratio in RLM than in HLM and MLM. However, DTZ is not likely a weak inactivator in RLM, since DTZ showed high kinact. This discrepancy may be due to a higher KI in RLM than in MLM or HLM.
To date, factors underlying species differences in CYP3A inactivation mediated by MBI are unknown. In the present study, we found that kinact/KI ratios (MBI potency) were negatively correlated with IC50 (reversible inhibition) (r＝-0.820, p＝0.0003) (Fig. 5) . Since IC50 obtained from a reversible inhibition experiment is considered to reflect primarily affinity of the inhibitor for the enzyme, 22, 24) these results suggest that species differences in MBI potency may be partly explained by the different affinity for each CYP3A of the parent inhibitor. In humans, differential MBI of CYP3A4 and CYP3A5 has been reported. 19, 22, 24) CYP3A5 is less efficient in forming a metabolic intermediate complex than CYP3A4. The smaller pharmacophore for CYP3A5 inhibition than that for CYP3A4 may possibly result in less energetic feasibility for inhibition by large-molecule inhibitors and less likelihood of secondary or tertiary metabolism. 22, 25) The differences in pharmacophores for CYP3A4 and CYP3A5 inhibition may determine conformational states of the heme environment and accessibility of the nitroso group in the metabolic intermediate to the heme. 24) Although the pharmacophore for CYP3A inhibition in rodents has not been clarified, differences in amino acid sequences in human, rat and mouse CYP3A [26] [27] [28] would probably result in differences in pharmacophores for binding to inhibitors and metabolic intermediates among species. Although further studies on metabolism of parent inhibitors in each species and pharmacophores for CYP3A inhibition in rodents are needed, our results suggest that the different affinity for each CYP3A of the inhibitor may partly explain species differences of CYP3A inactivation mediated by MBI.
The species differences in CYP3A between humans and rodents have limited the use of rodents as in vivo models for DDI study. In our preliminary study, MBI of CYP3A by ERM and CAM was observed not only in HLM but also in liver microsomes of CYP3A humanized mice. CYP3A humanized mice may be useful for study of CYP3A inactivation in vivo, especially for drugs showing species differences in MBI of CYP3A.
In conclusion, the results of the present study suggest that there are species differences in MBI of CYP3A in humans, rats and mice. Although the factors underlying species differences in CYP3A inactivation remain to be clarified, affinity of the parent inhibitor for CYP3A may contribute to differences in MBI potency among species. Therefore, species differences in MBI of CYP3A should be considered when rodents are used as in vivo models for MBI-mediated DDI study. Finally, future development of models for prediction of DDI arising from MBI of CYP3A using experimental animals in vivo is likely to come from a better understanding of enzymology of the CYP3A subfamily in each species and development of CYP3A humanized animals.
